
All News



Pharmaceutical Executive
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance


Pharmaceutical Executive
Ilogistica has built a brand new warehouse facility with the latest technology to keep up with outsourcing demands

Pharmaceutical Executive
Espacio Riesco has adapted to the needs of pharma companies with the largest event space in Chile

GSK's Deirdre Connelly puts the focus on four steps to cement a new compliance culture

Pharmaceutical Executive
Castellani Takes Charge at PhRMA

Pharmaceutical Executive
Boehringer Ingelheim's PICASSO program helps it focus on engaging industry stakeholders to improve patient care

Pharmaceutical Executive
Ferring finds a new approach to communicate its value offering

Pharmaceutical Executive
Ipsen is redefining a standard for success in innovation with its local Dutch affiliate

Prix Galien 2011 sponsorship brochure

Hotels, Convention Centers and Convention & Visitor Bureaus

Pharmaceutical Executive
The Promise Of Translational Medicine

Pharmaceutical Executive
The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest

PharmExec edit calendar revised and smaller size

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

June 2010 Sworn Statement

Pharmaceutical Executive
Once silent, an emerging market raises its voice

PharmExec 2011 online e-media rates


September 21, 2010.


September 08, 2010.

In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.

Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.

In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.

Pharmaceutical Executive
An industry struggling to meet expectations for new science may find the best strategy is the "controlled burn."

Pharmaceutical Executive
August 2, 2010.

Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.